Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia

Journal of Neural Transmission

Volumn 113, Issue 11, 2006, Pages 1787-1790

  Ceravolo, R ^a   Volterrani, D ^a   Frosini, D ^a   Bernardini, S ^a   Rossi, C ^a   Logi, C ^a   Manca, G ^a   Kiferle, L ^a   Mariani, G ^a   Murri, L ^a   Bonuccelli, U ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Acetylcholinesterase inhibitors; Dementia; Parkinson's disease; SPECT

Indexed keywords

CHOLINESTERASE INHIBITOR; CYSTEINE ETHYL ESTER TC 99M;

AGED; ARTICLE; BRAIN PERFUSION; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; DRUG EFFICACY; FEMALE; FRONTAL CORTEX; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

AGED; ANTIPARKINSON AGENTS; BRAIN; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PHENYLCARBAMATES; PIPERIDINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33750446286     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-006-0478-6     Document Type: Article

References (26)

1. D Aarsland M Hutchinson JP Larsen 2003 Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia Int J Geriatr Psychiatry 18 937 941
2. D Aarsland K Laake JP Larsen C Janvin 2002 Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study J Neurol Neurosurg Psychiatry 72 708 712
3. American Psychiatric Association (APA) (1994) Diagnostic and Statistical Manual of Mental Disorders, IV edn (DSM IV). American Psychiatric Association, Washington. DC
4. NI Bohnen DI Kaufer LS Ivanco 2003 Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease. An in vivo positron emission tomographic study Arch Neurol 60 1745 1748
5. JLW Bosboom D Stoffers Ech Wolters 2004 Cognitive dysfunction and dementia in Parkinson's disease J Neural Transm 111 1303 1315
6. R Ceravolo D Volterrani G Tognoni 2004 Cerebral perfusion effects of Cholinesterase inhibitors in Alzheimer disease Clin Neuropharmacol 27 166 170
7. M Emre D Aarsland A Albanese 2004 Rivastigmine for dementia associated with Parkinson's disease N Engl J Med 351 2509 2518
8. N Fournet O Moreaud J Roulin B Naegele J Pellat 2000 Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication Neuropsychology 38 252 271
9. N Giladi H Shabtai T Gurevich B Benbunan M Anca AD Korczyn 2003 Rivastigmine for dementia in patients with Parkinson's disease Acta Neurol Scand 108 368 373
10. J Glowinski 1990 Recent finding on dopaminergic transmission in the basal ganglia Adv Neurol 53 67 73
11. AJ Hughes SE Daniel L Kilford AJ Less 1992 Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 181 184
12. I Leroi J Brandt SG Reich CG Lyketsos S Grill R Thompson L Marsh 2004 Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease Int J Geriatr Psychiatry 19 1 8
13. G Levy MX Tang ED Louis 2002 The association of incident dementia with mortality in PD Neurology 59 1708 1713
14. G Linazasoro A Lasa N Van Blercom 2005 Efficacy and safety of donepezil in the treatment of exectuive dysfunction in Parkinson disease: a pilot study Clin Neuropharmacol 28 176 178
15. IG [tmp] McKeith T Del Ser P Spano 2000 Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study Lancet 356 2031 2036
16. I Nakano A Hirano 1984 Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease Ann Neurol 15 415 418
17. S Nakano T Asada H Matsuda M Uno M Takasaki 2001 Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease J Nucl Med 42 1441 1445
18. F Nobili P Vitali M Canfora 2002 Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients Clin Neurophysiol 113 1241 1248
19. S Pakrasi EB Mukaetova-Ladinska IG [tmp] McKeith JT O'Brien 2003 Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle Int J Geriatr Psychiatry 18 879 886
20. EK Perry L Kilford AJ Lees DJ Burn RH Perry 2003 Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs Ann Neurol 54 235 238
21. B Ravina M Putt A Siderowf 2005 Donepezil for dementia in Parkinson's disease: a randomised, double-blind, placebo controlled, crossover study J Neurol Neurosurg Psychiatr 76 903 904
22. P Tiraboschi LA Hansen M Alford 2000 Cholinergic dysfunction in diseases with Lewy bodies Neurology 54 407 411
23. A Venneri MF Shanks RT Staff 2002 Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease Neuroreport 13 83 87
24. EA Werber JM Rabey 2001 The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia J Neural Transm 108 1319 1325
25. KA Wesnes I [tmp] McKeith C Edgar M Emre R Lane 2005 Benefits of rivastigmine on attention in dementia associated with Parkinson disease Neurology 65 1654 1656
26. FM Zhou C Wilson JA Dani 2003 Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems Neuroscientist 9 23 36